Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 195.05

-0.4%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bob zagorin who wrote (21061)	5/18/1998 5:33:00 PM
From: Henry Niman	Read Replies (1) of 32384

LGND issued two press releases this evening. Two LGD1550 studies showed that it had fewer side effects than other retinoids and it did not induce its own metabolism. Phase II trials in head & neck and cervical cancers are planned. The second abstract was on the AIDS consortium Phase II data for treating KS with oral Panretin. A 37% response rate was achieved (identical to LGND's study on oral Panretin for KS). Responding patients were on PIs but had high HIV levels. There was no relationship between Panretin effect and HIV levels. NDA for topical Panretin for KS was slated for filing "soon".

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next